Traitement de consolidation dans les cancers de l’ovaire

  • J.-F. Geay
  • I. Ray-Coquard
  • H. Curé
  • É Pujade-Lauraine
Part of the Abord clinique book series (ONCOLPRAT)


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Thomas GM (1993) Is there a role in for consolidation or salvage radiotherapy after chemotherapy in advanced epithelial ovarian cancer? Gyn Oncol 51: 97–103CrossRefGoogle Scholar
  2. 2.
    Sorbe B (2003) Consolidation treatment of advanced ovarian carcinoma with radiotherapy after induction chemotherapy. Int J Gynecol Cancer 13Suppl 2: 192–5PubMedGoogle Scholar
  3. 3.
    Varia MA, Stehman FB, Bundy BN et al. (2003) Intraperitoneal radioactive phosphorus (32P) versus observation after negative second-look laparotomy for stage III ovarian carcinoma: a randomized trial of the Gynecologic Oncology Group. J clin Oncol 21: 2849–55CrossRefPubMedGoogle Scholar
  4. 4.
    Seiden M, Benigno B, The SMART study investigator group (2004) A pivotal phase III trial to evaluate the efficacy and safety of adjuvant treatment with R1549 (yttrium-90-labeled HMFG1 murine monoclonal antibody) in epithelial ovarian cancer. Proc Am Soc Clin Oncol 23 (abstr 5008)Google Scholar
  5. 5.
    Hakes TB, Chalas E, Hoskins WJ et al. (1992) Randomized prospective trial of 5 versus 10 cycles of cyclophosphamide, doxorubicin, and cisplatin in advanced ovarian carcinoma. Gynecol Oncol 45: 284–9CrossRefPubMedGoogle Scholar
  6. 6.
    Bertelsen K, Jakobsen I, Nielsen SK et al. (1993) A prospective randomized comparison of 6 and 12 cycles of cyclophosphamide, adriamycin and cisplatin in advanced epithelial ovarian cancer: A Danish Ovarian Study Group trial (DA-COVA). Gynecol Oncol 49: 30–6CrossRefPubMedGoogle Scholar
  7. 7.
    Lambert HE, Rustin GJ, Gregory WM et al. (1997) A randomized trial of five versus eight courses of cisplatin or carboplatin in advanced epithelial ovarian carcinoma: A North Thames Ovary Group Study. Ann Oncol 8: 327–33CrossRefPubMedGoogle Scholar
  8. 8.
    Scarfone G, Merisio C, Garavaglia E et al. (2002) A phase III trial of consolidation versus NIHIL (NIL) for advanced epithelial ovarian cancer (AEOC) after complete remission (CR). Proc Am Soc Clin Oncol 21: 204a (abstr 812)Google Scholar
  9. 9.
    Pfisterer J, Lortholary A, Kimmig R et al. (2003) Paclitaxel/carboplatin (TC) versus paclitaxel/ carboplatin followed by topotecan (TC-Top) in first-line treatment of ovarian cancer FIGO stages IIb-IV: Interim results of a gynecologic cancer intergroup phase III trial of the AGO Ovarian Cancer Study Group and GINECO. Proc Am Soc Clin Oncol 22: 446 (abstr 1793)Google Scholar
  10. 10.
    Pignata S, Deplacido S, Scambia G et al. (2003) Topotecan versus nihil after response to carboplatin and paclitaxel in advanced ovarian cancer: Early results of the MITO-1 (Multicenter Italian Trials in Ovarian Cancer) study. Proc Am Soc Clin Oncol 22: 446 (abstr 1791)Google Scholar
  11. 11.
    Piccart MJ, Floquet A, Scarfone G et al. (2003) Intraperitoneal cisplatin versus no further treatment: 8-year results of EORTC 55875, a randomized phase III study in ovarian cancer patients with a pathologically complete remission after platinum-based intravenous chemotherapy. Int J Gynecol Cancer 13: 196–203 (suppl 2)PubMedGoogle Scholar
  12. 12.
    Markman M, Liu PY, Wilczynski S et al. (2003) Phase III randomized trial of 12 versus 3 months of maintenance paclitaxel in patients with advanced ovarian cancer after complete response to platinum and paclitaxel-based chemotherapy: A Southwest Oncology Group an Gynecologic Oncology Group trial. J Clin Oncol 21: 2460–5PubMedGoogle Scholar
  13. 13.
    Cure H, Battista C, Guastalla JP et al. (2001) Phase III randomized trial of high-dose chemotherapy (HDC) and peripheral blood stem cell (PBSC) support as consolidation in patients (pts) with advanced ovarian cancer (AOC): 5-year follow-up of a GINECO/FNCLCC/SFGM-TC study. Proc Am Soc Clin Oncol 20: 204a (abstr 815)Google Scholar
  14. 14.
    Hall G, Coleman R, Stead M et al. (2000) Maintenance treatment with interferon for advanced ovarian cancer. Proc Am Soc Clin Oncol 19: 386a (abstr 1529)Google Scholar
  15. 15.
    Berek J, Ehlen T, Gordon A et al. (2001) Interim analysis of a double blind study of Ovarex mAB B43.13 (OV) versus placebo (PBO) in patients with ovarian cancer. Proc Am Soc Clin Oncol 20: 210a (abstr 837)Google Scholar
  16. 16.
    Hirte HW, Vergote IB, Jeffrey JR et al. (2001) An international multicentre phase III study of BAY 12-9566 (BAY) versus placebo in patients (pts) with advanced ovarian cancer (OVCA) responsive to primary surgery-paclitaxel + platinum containing chemotherapy (CT). Proc Am Soc Clin Oncol 20: 211a (abstr 843)Google Scholar

Copyright information

© Springer-Verlag France 2006

Authors and Affiliations

  • J.-F. Geay
  • I. Ray-Coquard
  • H. Curé
  • É Pujade-Lauraine

There are no affiliations available

Personalised recommendations